HomeCompareACGX vs ABBV

ACGX vs ABBV: Dividend Comparison 2026

ACGX yields 5464.48% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACGX wins by $147603083095830.66M in total portfolio value
10 years
ACGX
ACGX
● Live price
5464.48%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$147603083095830.75M
Annual income
$142,474,173,855,860,200,000.00
Full ACGX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ACGX vs ABBV

📍 ACGX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACGXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACGX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACGX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACGX
Annual income on $10K today (after 15% tax)
$464,480.87/yr
After 10yr DRIP, annual income (after tax)
$121,103,047,777,481,160,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ACGX beats the other by $121,103,047,777,481,150,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACGX + ABBV for your $10,000?

ACGX: 50%ABBV: 50%
100% ABBV50/50100% ACGX
Portfolio after 10yr
$73801541547915.42M
Annual income
$71,237,086,927,930,110,000.00/yr
Blended yield
96.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ACGX
No analyst data
Altman Z
-17.7
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACGX buys
0
ABBV buys
0
No recent congressional trades found for ACGX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACGXABBV
Forward yield5464.48%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$147603083095830.75M$102.3K
Annual income after 10y$142,474,173,855,860,200,000.00$24,771.77
Total dividends collected$147257041427200.94M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ACGX vs ABBV ($10,000, DRIP)

YearACGX PortfolioACGX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$557,148$546,448.09$11,550$430.00+$545.6KACGX
2$29,049,654$28,453,505.31$13,472$627.96+$29.04MACGX
3$1,417,590,924$1,386,507,794.43$15,906$926.08+$1417.58MACGX
4$64,750,508,711$63,233,686,422.09$19,071$1,382.55+$64750.49MACGX
5$2,768,619,277,821$2,699,336,233,500.13$23,302$2,095.81+$2768619.25MACGX
6$110,830,580,077,440$107,868,157,450,171.88$29,150$3,237.93+$110830580.05MACGX
7$4,154,167,693,124,137$4,035,578,972,441,277.00$37,536$5,121.41+$4154167693.09MACGX
8$145,811,454,439,203,650$141,366,495,007,560,800.00$50,079$8,338.38+$145811454439.15MACGX
9$4,793,373,121,467,805,000$4,637,354,865,217,857,000.00$69,753$14,065.80+$4793373121467.74MACGX
10$147,603,083,095,830,760,000$142,474,173,855,860,200,000.00$102,337$24,771.77+$147603083095830.66MACGX

ACGX vs ABBV: Complete Analysis 2026

ACGXStock

Alliance Creative Group, Inc. operates as a creative packaging and digital engagement company in the United States. The company provides creative and design services, including advertising campaigns, art direction, brand identity, graphic design, strategy and planning, logo design, Website design, collateral design, video production, conversion copywriting, blog and keyword planning, package design, and photography; and club packs, corrugate, flexible, folding carton, pallet display, pre-print, custom, stock, and thermo-forming packaging services. It also offers supply chain management services, such as third-party logistics, trucking and distribution, vendor managed inventory, and warehousing; commercial, digital, direct mail, grand format, large format, offset, catalog, design support, outdoor signage, and Web printing services; and brand audit and research, brand strategy, communication planning, content planning, event planning, event advisory, and PR advisory services. In addition, the company provides content creation, online marketing, customer engagement, business consulting and strategic marketing, software development, digital engagement, and logistics/VMI services. It offers its services under the St. Louis Packaging, STL Graphics, Snap Graphics, Print4aCause, CoporateGifts4aCause, and PeopleVine brand names to automotive, beauty and wellness, confectionery, food and beverage, gaming and electronics, home enhancement, music and entertainment, pet care, restaurant, sports, technology, and wine and spirits industries. The company was formerly known as Invicta Group, Inc. and changed its name to Alliance Creative Group, Inc. in November 2010. Alliance Creative Group, Inc. was founded in 2000 and is headquartered in East Dundee, Illinois.

Full ACGX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ACGX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACGX vs SCHDACGX vs JEPIACGX vs OACGX vs KOACGX vs MAINACGX vs JNJACGX vs MRKACGX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.